CONROE, Texas, Oct. 14, 2025 /PRNewswire/ –Next Level is proud to announce the expansion of its…
Category: News
iOnctura debuts cambritaxestat (IOA-289) clinical data in patients with pancreatic cancer at ESMO
Cambritaxestat, the first autotaxin (ATX) inhibitor to be investigated in cancer patients, meets its primary endpoint…
EVOQ Therapeutics Awarded $2 Million NIH Grant to Advance Therapies to Treat Celiac Disease – An Autoimmune Disease Impacting 2.4 Million Americans
ANN ARBOR, Mich. and CHICAGO, Oct. 14, 2025 /PRNewswire/ — EVOQ Therapeutics, Inc. (EVOQ) a biopharmaceutical…
Cortechs.ai Acquires ZepMed to Expand AI-Powered Neuroimaging Capabilities
SAN DIEGO, Oct. 14, 2025 /PRNewswire/ — Cortechs.ai, a leader in AI-driven neuroimaging software, today announces…
11 Years of Global Patient Week: Bristol Myers Squibb Brings Joy to Patients with Toy-Making Workshops Across the Region
Bristol Myers Squibb employees in Riyadh and Dubai collaborated with local PAGs to host patient-centered toy-making…
FWA Insights: Appropriate billing of intensive outpatient programs
The appropriate billing of intensive outpatient programs (IOPs) for psychiatric services is essential to ensuring the…
10x Faster Virus Neutralization Testing With Launch of Integral Molecular’s Ready Reporter Virus™ Kit
Automation-compatible, safe assay delivers same-day results to accelerate vaccine and therapeutic antibody development PHILADELPHIA, Oct. 14,…
Infosys Chosen by NHSBSA to Deliver a New Workforce Management Solution for the NHS in England and Wales
Next-Generation solution supports the NHS 10-year Health Plan and the mission to create a workforce that…
Twin Health and Peloton Partner to Transform Metabolic Health
The unique partnership will bring Peloton’s world-class fitness and wellness content to Twin’s AI digital twin…
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
A retrospective cohort study of claims data demonstrated that following hospital discharge, patients adherent toYUPELRI experienced…